The T-box transcription factor TBX3 provides an important link between embryonic development and cancer. TBX3 mediates limb, mammary gland and heart development and, in humans, mutations resulting in haplo-insufficiency of TBX3 lead to ulnarmammary syndrome. Importantly, the de-regulation of TBX3 gene expression has been linked to several cancers, where it acts to suppress senescence and promotes proliferation and tumour invasion. Despite the negative impact of de-regulated TBX3 expression as seen by developmental defects and cancer, surprisingly little is known about the regulation of the TBX3 gene. In the present paper, we show that the phorbol ester PMA increases TBX3 protein and mRNA levels in a protein kinase C-dependent manner via the AP-1 (activator protein 1) transcription factors c-Jun and JunB. Furthermore, these AP-1 factors are shown to mediate the activation of the TBX3 gene by binding a non-consensus PMA-response element in the TBX3 promoter in vitro and in vivo. We also demonstrate that TBX3 contributes to the PMA-induced migration previously observed for the MCF-7 breast epithelium cancer cell line. Our present results reveal a previously unidentified pathway that up-regulates TBX3 expression and provides additional evidence that increased levels of TBX3 contribute to metastasis.
INTRODUCTION
TBX3, a member of the developmentally important T-box family of transcription factors, is expressed in many tissues during embryogenesis and acts as a transcriptional repressor [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Its essential role in embryonic development is underscored by the observations that Tbx3-homozygous mutations in mice lead to embryonic lethality [13] and Tbx3-heterozygous mice display limb and mammary gland abnormalities. Furthermore, UMS (ulnar-mammary syndrome), a congenital autosomal-dominant disorder, is caused by mutations that result in haplo-insufficiency of the human TBX3 protein. UMS is characterized by upperlimb anomalies and mammary gland hypoplasia, as well as hair, genital and dental defects [14, 15] . In addition to its critical role in development, accumulating evidence points to a major role for TBX3 in tumorigenesis. TBX3 is overexpressed in many cancers, including breast, melanoma and bladder cancers [16] [17] [18] [19] [20] [21] , and previous findings suggest that it contributes to the oncogenic process, in part, by its ability to bypass senescence through repressing the cyclin-dependent kinase inhibitors p19 ARF and p21
CIPI [22] [23] [24] [25] . Interestingly, increased levels of TBX3 were recently reported to enhance melanoma invasiveness by directly repressing expression of the adhesion molecule Ecadherin [26, 27] . Taken together, the above findings suggest that TBX3 has the ability to contribute to different stages of cancer progression and that tight regulation of TBX3 levels is critical for normal cellular function. Surprisingly, however, little is known about the regulation of TBX3 gene expression.
PKC (protein kinase C) represents an important multigene family of serine/threonine kinases that plays a major role in signaltransduction pathways and has functions in many physiological and pathological processes [28] [29] [30] . PKC can be activated by various extracellular and intracellular signals and is a major intracellular target of the phorbol ester PMA (also called TPA), which is commonly used as an extracellular signal to activate PKC enzymes [31, 32] . It is well established that, in response to PMA, the activator protein-1 (AP-1) family of transcription factors is activated, leading to an increase in their target-gene expression [33, 34] . AP-1 factors (Fos, Fra-1, Fra-2, FosB, c-Jun, JunB and JunD) play critical roles in many cell processes, such as proliferation, differentiation, apoptosis, oncogene-induced transformation and cellular invasion [35, 36] . Physiologically active AP-1 complexes, which are composed of either Jun homodimers or Jun and Fos heterodimers, control both basal and inducible target-gene expression via binding to the consensus TRE (PMA-response element) (TGAG/CTCA) in addition to nonconsensus binding elements [37] [38] [39] . One mechanism via which PMA can lead to the activation of AP-1 factors is by direct PKCdependent transcriptional activation. For example, Kieser et al. [40] demonstrated that the PKC-θ isoform can directly target the JunB promoter in NIH3T3 cells. In another study, PKC-ε was found to up-regulate JunB through the mitogen-activated protein kinase pathway [41] . It is therefore evident that the precise mechanism of transcriptional activation of AP-1 by PMA varies for different PKC isoforms.
In the present study, we demonstrate, using several cell lines, that PMA activates TBX3 gene expression in a PKC-dependent manner via the AP-1 transcription factors c-Jun and JunB. These AP-1 factors are shown to bind a non-consensus TRE in the TBX3 promoter in vitro and in vivo. We also demonstrate that TBX3 contributes to the PMA-induced migration previously observed for the MCF-7 breast epithelium cancer cell line [42] . Taken together, the results reveal a mechanism by which TBX3 levels are up-regulated and provide additional evidence that increased levels of TBX3 contribute to metastasis.
EXPERIMENTAL

Cell cultures and treatments
MRC-5 normal human fetal lung fibroblast (provided by Professor Colin Goding, Nuffield Department of Medicine, Ludwig Institute of Cancer Research, University of Oxford), PNT1A normal human prostate epithelium (provided by Professor Nicolas Novitzky, Division of Haematology, University of Cape Town), CaSki human epithelial cervical carcinoma (provided by Dr Virna Leaner, Division of Medical Biochemistry, University of Cape Town) and HT-1080 human fibrosarcoma (provided by Professor Iqbal Parker, International Centre for Genetic Engineering and Biotechnology, University of Cape Town) cells were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) FBS (fetal bovine serum), 200 units/ml penicillin and 100 μg/ml streptomycin. MCF-7 human breast epithelial adenocarcinoma cells were cultured in RPMI 1640 supplemented with 10 % (v/v) FBS, 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids (Highveld Biological), 0.01 mg/ml insulin, 200 units/ml penicillin and 100 μg/ml streptomycin. Cells were maintained in a 37
• C incubator (95.0 % air/5 % CO 2 , 65 % humidity). Doxycycline-inducible Tam67 CaSki clones were established using the retroviral plasmid pLRT-Tam67 (provided by Dr Michael Birrer, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.), which contains a doxycycline-inducible c-Jun transactivation mutant, TAM67 [43] . pLRT-Tam67 was transfected into Phoenix A cells, a retroviral-packaging cell line, using the standard calcium phosphate transfection procedure. Fresh medium was added 24 h after transfection, and cells were incubated for an additional 48 h before harvesting the retrovirus-containing medium. CaSki cells were infected with pLRT-Tam67 retrovirus in DMEM/10 % FBS for 48 h at 37
• C. Stable doxycycline-inducible Tam67-expressing clones were selected in the presence of 5 μg/ml blasticidin. Clones with inducible Tam67 expression were screened by Western blot analysis after induction with 1 μg/ml doxycycline for 48 h. Cells were serum-starved 16 h prior to treatment with PMA or EGF (epidermal growth factor), which was added directly to the medium at final concentrations of 100 nM or 50 ng/ml respectively. For PKC-inhibitor treatments, cells were pretreated for 2 h with either 20 μM GF109203X (Calbiochem) or 50 μM curcumin (Sigma-Aldrich), prior to addition of PMA. For expression of TAM67, cells were treated with 2 μg/ml doxycycline 48 h prior to addition of PMA.
Western blot analyses
Whole cell extracts were prepared from cells using RIPA lysis buffer: 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS, 10 mM Tris/HCl, pH 7.5, and 1 % deoxycholate, supplemented with 1 mg/ml aprotinin, 1 mg/ml Pepstatin A and 2 mM phenylmethanesulfonyl fluoride protease inhibitors (SigmaAldrich). Proteins were resolved by SDS/PAGE (8-12 % gels) as required and transferred to Hybond ECL membranes (Amersham Biosciences). The membranes were probed with appropriate primary antibodies and detected using peroxidase-conjugated anti-mouse or anti-rabbit antibodies and visualized by ECL (enhanced chemiluminescence) (Pierce). The primary antibodies used were as follows: rabbit polyclonal anti-TBX3 antibody (1:250 dilution) (Zymed 42-4800; Zymed Laboratories); rabbit polyclonal anti-p38 antibody (1:5000 dilution) (Cell Signaling • C). Each DNA sample was quantified in duplicate and a negative control without cDNA template was run with every assay to assess the overall specificity. Melting-curve analyses were carried out to ensure product specificity and data were analysed using the 2 − Ct method [23] . Relative mRNA expression levels were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) for each reaction, with the PCRefficiency correction calculated using the following equation:
where E is real-time PCR efficiency and CP is crossingpoint. Primers used to amplify human TBX3 (catalogue no. QT00022484) were purchased from Qiagen. Primers used for GAPDH amplification were: forward, 5 -GAAGGCTGGGGCT-CATTT-3 ; and reverse, 5 -CAGGAGGCATTGCTGATGAT-3 .
ChIP (chromatin immunoprecipitation) assays
ChIP assays were carried out as described previously [44] . Briefly, PNT1A cells (60-70 % confluency) were serumstarved 24 h prior to treatment with PMA or vehicle. Cells were fixed in 1 % formaldehyde after 4 h of treatment. The chromatin was extracted, sonicated and immunoprecipitated using antibodies against c-Jun and JunB (Santa Cruz Biotechnology) or IgG (Bio-Rad Laboratories). DNA precipitation was analysed by PCR using human TBX3-specific primer pairs (forward, 5 -GGAGTGCAAGAGAGGCGAGC-3 ; reverse, 5 -CTCGCTCGCTCTGGTTCAGC-3 ).
Nuclear protein extraction
Nuclear extracts were prepared from untreated and PMA-treated (4 h) PNT1A cells using the method of Dignam et al. [44] . Briefly, confluent cells from 10-cm-diameter dishes were washed twice with ice-cold PBS. After washing, cells were harvested in ice-cold PBS by scraping and pelleted at 1000 g for 5 min at 4 • C. Packed cells were resuspended in 1 vol. of buffer A [10 mM Hepes, pH 8.0, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM DTT (dithiothreitol), 1 μg/ml aprotinin and 1 μg/ml Pepstatin A] and allowed to swell on ice for 15 min, and then lysed with a 26-gauge needle. The homogenate was centrifuged for 20 s at maximum speed in a bench-top centrifuge and the nuclear pellet resuspended in twothirds of packed-cell volume of buffer C [20 mM Hepes, pH 8.0, 1.5 mM MgCl 2 , 25% (v/v) glycerol, 420 mM NaCl, 0.2 mM EDTA, pH 8.0, 1 mM DTT, 0.5 mM PMSF, 1 μg/ml aprotinin and 1 μg/ml Pepstatin A). After stirring on ice for 30 min, nuclear debris was pelleted by centrifugation for 5 min in a bench-top centrifuge at maximum speed. The nuclear extract was dialysed for 2 h against buffer D (20 mM Hepes, pH 8.0, 20 % glycerol, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 1 μg/ml aprotinin and 1 μg/ml Pepstatin A).
EMSA (electrophoretic mobility-shift assay)
Probes WT (5 -GCTGGATGACTGAGGCATTTCAG-3 ), AP-371 Mut (5 -GCTGGACGATCGTGGCATTTCAG-3 ), AP-367 Mut (5 -GCTGGATGACCGATGTATTTCAG-3 ) and AP-371/ 367 Mut (5 -GCTGGACGATCGTTGTATTTCAG-3 ) and their corresponding complementary sequences were synthesized and annealed. The WT probe was radioactively 5 -end-labelled with [ 32 P]-γ ATP using polynucleotide kinase (Roche). Gel-shift conditions were as follows: 50 μg of protein, 4 μl of polydI/C (1 μg/ml) and 1 μl of labelled probe (2500 c.p.m./0.3 ng) were brought to a final volume of 40 μl using 5× incubation buffer [100 mM Hepes, pH 7.9, 250 mM KCl, 2.5 mM DTT, 10 mM EDTA, 5 mM MgCl 2 and 20 % (v/v) Ficoll 400]. Competition assays were performed using a 100× molar excess of unlabelled probe. For supershift analysis, 15 μg of antibody was used and incubated for 1 h. DNA-protein complexes were resolved by nondenaturing PAGE (5 % gels) at 4
• C in 0.5× TBE (22.5 mM Tris/borate and 0.5 mM EDTA). Gels were dried and exposed to X-ray film for 24 h.
Plasmid constructs
The human TBX3-promoter luciferase reporter was generated by amplifying the − 1483 bp to +40 bp region of the promoter by PCR using a forward primer harbouring an NheI site (5 -GTTGGCTAGCCGGCGATTGGTAAGATC-3 ) and a reverse primer harbouring a BglII site (5 -GCGAAGATCTCG-AGAGCTCCTCGCCAC-3 ). Then, the PCR fragment was purified, digested with the appropriate restriction endonucleases and ligated into the pGL3-Basic luciferase reporter vector (Promega). The integrity of the DNA fragment was verified by automated BigDye Terminator sequencing using an AB PRISM ® 3100 Genetic Analyzer (Applied Biosystems) and confirmed by alignment with the human genomic DNA database. The pCMV-c-Jun and pCMV-JunB expression vectors were generously provided by Dr Michael Birrer (National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.).
Transfection and luciferase assays
Transient transfections were performed using FuGENE HD (Roche) according to the manufacturer's instructions. Cells were plated at 1.5 × 10 5 cells/ml in 35-mm-diameter dishes 16 h before transfection. HT-1080 cells were transfected with 700 ng of the TBX3-luciferase reporter plasmid plus 200 ng of the c-Jun or JunB expression plasmid or 200 ng of an empty-vector plasmid. The vector pRL-CMV (Promega) containing the cytomegalovirus promoter driving the expression of a Renilla reporter was used as an internal control for transfection efficiency (10 ng/35 mm dish). Cells were cultured for 30 h and extracts were assayed for firefly and Renilla luciferase activity using the dual-luciferase assay system (Promega). Luciferase activities were measured using the Luminoskan Ascent luminometer (Thermo Labsystems). Firefly luciferase values were normalized to the Renilla luciferase activity and expressed relative to empty-vector control. Suppression of TBX3 expression in MCF-7 cells was achieved by an siRNA (small interfering RNA) that specifically targets TBX3 mRNA. The cells were transfected with 5 nM anti-TBX3 siRNA or a control (non-silencing) siRNA (Qiagen), using HiPerFect reagent (Qiagen, U.S.A.) according to the manufacturer's instructions.
All transfections were performed in duplicate and at least three independent experiments were carried out to confirm reproducibility.
Site-directed mutagenesis of the TBX3 promoter
The WT TBX3-luc (luciferase) plasmid was modified as follows. The AP-371 site, 5 -TGACTGA-3 located at position − 371 bp, was mutated to 5 -CGATCGT-3 by site-directed mutagenesis using an adapted protocol supplied by the Stratagene QuickChange system and the primer pair 5 -GATCCCCGGCT-GGACGATCGTGGCATTTCAGACGTGAC-3 and 5 -GTCAC-GTCTGAAATGCCACGATCGTCCAGCCGGGGATC-3 . Successful introduction of the mutation was confirmed by automated BigDye Terminator sequencing using the AB3100 Genetic Analyzer (Applied Biosystems).
In vitro cell-migration assays
For the in vitro scratch motility assay, MCF-7 cells were transfected with 5 nM of either siTBX3 or sictrl (si control) oligonucleotide (48 h ) and grown to confluence on tissue-culture dishes under standard growth conditions. A linear wound was made by scratching through the monolayer using a sterile Gilson 200-μl pipette tip. To remove cell debris the growth medium was replaced, and to prevent cell proliferation mitomycin C (Sigma-Aldrich) was added at a final concentration of 10 μg/ml. Several markings were made along the edges of the scratch line that were used as reference points, and the wound widths were measured at the time of the scratching (0 h) and at 1, 3, 5 and 7 h. To induce migration in the MCF-7 cells, PMA was added at a final concentration of 100 nM. Photographs were taken using a fluorescent microscope and migration distances were measured using Axzio software (Zeiss). The difference in width represents the distance migrated in micrometres. Migration assays using two independent TBX3 siRNAs were carried out in triplicate and performed twice to confirm reproducibility. For the transwell cell-migration assay, transwell plates with 8-μm pore size coated with basement membrane matrix (ThinCert TM cell-culture inserts; Greiner) were used. MCF-7 cell lines stably expressing a sh (small-hairpin) TBX3 or shcontrol [27] were seeded at 1 × 10 5 cells/ml in serumfree RPMI 1640 medium (containing either 100 nM PMA or DMSO) to the top chamber and incubated for 24 h at 37
• C. The bottom chamber contained RPMI 1640 supplemented with 10 % (v/v) FBS (containing either 100 nM PMA or DMSO). After incubation, cells were fixed in 100 % methanol and cotton swabs were used to remove cells in the upper surface of the transwells. Migrated cells attached to the undersurface of the transwell were stained with crystal violet solution and then airdried. Crystal violet-stained migrated cells were solubilized in 150 μl of 50 % (v/v) acetic acid and quantified using a microplate reader at 595 nm. Experiments were performed in triplicate to confirm reproducibility.
RESULTS
PMA up-regulates TBX3 protein and mRNA levels via the PKC pathway
The phorbol ester PMA is known to enhance the mobility and invasion of tumorigenic cell lines with low metastatic abilities [42, 45] . TBX3 is overexpressed in several cancers and recent findings reveal a potential relationship between TBX3 overexpression and tumour invasiveness [26, 27] . It is therefore important for TBX3 levels to be tightly regulated within the PMA up-regulates TBX3 mRNA levels. The same cell lines were treated with PMA as above and total RNA was extracted at the times indicated. qRT-PCR was performed on reverse-transcribed RNA using primers specific to TBX3, and mRNA levels were normalized to GAPDH.
cell, since loss of regulation leads to detrimental consequences. However, very little is known about how TBX3 is regulated, and in the present study we therefore ask whether the PMA signalling pathway can regulate TBX3 expression in the normal human prostate epithelial and lung fibroblast cell lines PNT1A and MRC-5 respectively. These cells, which express detectable levels of TBX3, were treated with 100 nM PMA for 2 h, 4 h and 8 h and TBX3 levels analysed by Western blot analyses. Our results showed that PMA significantly induced TBX3 expression, with levels increasing at all time points and peaking at 4 h in both cell lines tested ( Figure 1A) , suggesting that the PMA signalling pathway plays an important role in the regulation of TBX3. The expression of p38 protein was used as a loading control and illustrated equal loading of protein samples.
In order to determine whether the above induction of TBX3 expression by PMA is due to an increase in transcription, cells were treated with or without PMA for a period spanning 2-8 h and TBX3 mRNA levels were assessed by qRT-PCR. As observed for protein levels, our results showed that TBX3 mRNA levels were up-regulated at all time points in MRC-5 cells with the highest levels obtained at 2 h ( Figure 1B) . Similarly, TBX3 mRNA levels increased when PNT1A cells were treated with PMA ( Figure 1B) . TBX3 mRNA levels therefore closely correlated with levels of TBX3 protein, which suggested that PMA induced TBX3 expression at a transcriptional level.
PKC, a serine/threonine kinase, has been identified as a highaffinity receptor for the phorbol ester PMA [31, 32] and therefore we next established whether PMA-induced TBX3 expression was mediated by a PKC-dependent pathway. To this end, we pretreated PNT1A cells with an inhibitor specific to PKC prior to PMA treatment and then analysed TBX3 expression by qRT-PCR. The PKC inhibitor GF109203X reduced PMA-induced TBX3 mRNA and protein levels, which suggested that PKC is an important mediator of TBX3 regulation by the PMA pathway (Figure 2A , left panel, and Figure 2B ). Importantly, when PMA was replaced with EGF, a known stimulator of the PKC pathway, similar results were obtained, demonstrating the physiological relevance of PKC in the regulation of TBX3 (Figure 2A, right panel) . Furthermore, curcumin, another known PKC inhibitor [46] , also inhibited PMA-mediated regulation of TBX3, confirming the role of PKC in the regulation of TBX3 by PMA ( Figure 2B ).
PMA-induced TBX3 expression is mediated by AP-1 family members
It is well documented that PMA induces the expression of numerous genes through up-regulation of AP-1 and we therefore Total RNA was isolated and qRT-PCR was performed on reverse-transcribed RNA using primers specific to TBX3, and mRNA levels were normalized to GAPDH. (B) PNT1A cells were pretreated with vehicle (control) or 20 μM PKC inhibitor (GF109203X) or 50 μM curcumin for 2 h followed by PMA (100 nM) for 4 h. Whole lysates were harvested and proteins were separated by SDS/PAGE (8 % gel) and analysed by Western blotting with antibodies to TBX3. p38 was detected as a loading control. examined the expression of AP-1 family members in PNT1A and MRC-5 cells treated with or without PMA by Western blot analyses. Our results showed that PMA treatment increased several AP-1 family members, such as c-Jun, JunB and c-Fos ( Figures 3A and 3B) . Importantly, this increase correlated with an up-regulation of TBX3 in both cell lines tested. To investigate whether the PMA-induced TBX3 expression is indeed via AP-1, we tested the effect of PMA on endogenous TBX3 expression in two CaSki cell lines engineered to express an inducible dominant negative AP-1 (TAM67) which squelches AP-1 and blocks its ability to bind DNA as previously described [47] . To this end, cells were pretreated with doxycycline to induce TAM67 expression before PMA treatment, and TBX3 mRNA levels were analysed by qRT-PCR ( Figure 3C ) and Western blot analyses ( Figure 3D ). Our results show that PMA treatment resulted in an increase in the levels of TBX3 in both parental cells and in CaSki clones in which TAM67 had not been induced. This PMA-induced TBX3 expression was, however, only blocked in the TAM67-expressing cells treated with doxycycline, confirming that AP-1 mediates the observed effects of PMA on TBX3 expression.
AP-1 activation of the TBX3 promoter is mediated by the AP-371 TRE site
To investigate whether c-Jun/JunB directly binds the TBX3 promoter, we first examined a ∼ 1.5 kb genomic sequence upstream of the known 5 -UTR (untranslated region) of the human TBX3 gene and identified four non-consensus TREs. The first ( − 1304 to − 1297), second ( − 371 to − 364), third ( − 367 to − 360) and fourth ( − 158 to − 151) binding sites were designated AP-1304, AP-371, AP-367 and AP-158 respectively. Next, we performed a ChIP assay to verify that c-Jun/JunB could bind the TBX3 promoter directly in vivo. PMA-treated PNT1A cells were fixed with formaldehyde and the cross-linked chromatin was extracted and sheared. cJun/JunB-bound chromatin was immunoprecipitated with the appropriate antibodies. After reversing the cross-link, we used three sets of primers spanning regions of the TBX3 promoter containing putative TRE sites ( Figure 4A ) to amplify regions of the immunoprecipitated DNA. The result obtained ( Figure 4B ) indicated that only primers spanning AP-371 and AP-367 yielded a specific PCR product when using a mixture of anti-c-Jun and anti-JunB antibodies, but not using non-specific IgG as a control.
To demonstrate that c-Jun/JunB specifically binds the AP-371 and/or AP-367 sites(s) in the TBX3 promoter, we used a nuclear extract isolated from PMA-treated PNT1A cells and a radioactively labelled probe containing wild-type AP-371 and AP-367 ( Figure 4C , upper panel) in an in vitro DNA-binding assay. Three complexes were observed ( Figure 4C, lane 2) , one of which corresponded to c-Jun/JunB as determined using antic-Jun/JunB polyclonal antibodies, which resulted in a supershift and an increase in the stability of the complexes ( Figure 4C,  lanes 7 and 8) . To determine whether c-Jun/JunB binds AP-371 and/or AP-367, we used non-radioactive competitor oligonucleotides in which these sites were mutated ( Figure 4C , upper panel). The bound c-Jun/JunB was competed efficiently by the homologous wild-type oligonucleotide ( Figure 4C , lane 3) and the oligonucleotide in which only the AP-367 was mutated ( Figure 4C, lane 5) . The oligonucleotides containing either a mutated AP-371 or both AP-371 and AP-367 were not able to compete with the radioactively labelled WT probe ( Figure 4C, lanes 4 and 6) . Taken together, these results suggest that c-Jun and JunB form protein complexes at AP-371 in the TBX3 promoter and that TBX3 is a c-Jun/JunB target. Figure 1(A) . (C) PMA-induced TBX3 mRNA expression is mediated by AP-1. The CaSki parental cell line and two inducible TAM67-CaSki cell lines were pretreated for 48 h with vehicle (control) or 2 μg/ml doxycycline (to induce TAM67) and then treated with PMA (100 nM) for 4 h. Total RNA was isolated and qRT-PCR was performed on reverse-transcribed RNA using primers specific to TBX3, and mRNA levels were normalized to GAPDH. (D) PMA-induced TBX3 protein expression is mediated by AP-1. Whole cell extracts from cells treated above were separated by SDS/PAGE (8 % gel) and analysed by Western blotting with antibodies to TBX3. p38 was detected as a loading control.
To determine whether the interaction of AP-1 components at AP-371 in the TBX3 promoter is functional, a 1483 bp region of genomic sequence upstream of the known 5 -UTR of the human TBX3 gene was isolated from PNT1A cells, sequenced, cloned into the pGL3-Basic luciferase reporter vector and tested in transient-transfection assays. PMA treatment of HT-1080 cells transfected with this construct showed a 1.5-fold increase in promoter activity ( Figure 4D ). Importantly, co-transfection with c-Jun or JunB expression vectors led to an approx. 5.5-fold and 3.5-fold increase in TBX3 promoter activity respectively. Using site-directed mutagenesis, AP-371 was mutated and promoter activity in the presence of c-Jun and JunB was determined in HT-1080 cells. The mutation that was introduced changed the AP-371 binding site from TGACTGA to cGAtcGt and resulted in an abrogation of the activation observed for c-Jun and JunB ( Figure 4D ). This result, together with in vivo and in vitro binding assays, provides substantial evidence suggesting that c-Jun/JunB binds and activates the TBX3 promoter in vivo.
PMA-induced migration of MCF-7 cells is affected by TBX3 expression
As mentioned earlier, PMA is known to enhance the mobility and invasion of tumorigenic cell lines with low metastatic abilities [42, 45] . Interestingly, the migration ability of breast cancer MCF-7 cells was previously shown to increase in response to PMA treatment [42] and these cells express high levels of TBX3 [17] . Since recent findings have implicated increased TBX3 expression with metastasis, we hypothesized that TBX3 may be required for the PMA-induced migration of MCF-7 cells. To test this hypothesis, we first confirmed that treatment of MCF-7 cells with PMA leads to an increase in TBX3 protein ( Figure 5A ). Next, we knocked down TBX3 in MCF-7 cells using two independent siRNA sequences specific to TBX3 to exclude any off-target effects ( Figure 5B ) and compared the migration ability of these cells to control cells transfected with scrambled siRNA (control) in an in vitro scratch motility assay. As expected, a significant increase in migration was observed in control cells (sictrl) treated with PMA ( Figure 5C ). PMA-treated MCF-7 cells expressing both siTBX3s, however, had reduced migration ability ( Figure 5C ). This observation was confirmed in a second in vitro migration assay using transwell chambers coated with basement-membrane matrix and MCF-7 cells in which TBX3 was stably knocked down. Cell migration was allowed to proceed for 24 h in the presence or absence of PMA and, whereas a significant number of control MCF-7 cells (shctrl) migrated across the membrane, migration of shTBX3 cells was significantly inhibited ( Figure 5C ). These observations strengthen the possibility that TBX3 overexpression potentiates the metastatic ability of cells, which may involve a PMA-inducible pathway.
DISCUSSION
TBX3 plays an essential role in embryonic development, and mutations that result in haplo-insufficiency of the human TBX3 protein leads to UMS [14, 15] . In the last decade, there has been an emergence of compelling evidence to support a role for TBX3, and its closely related family member TBX2, in cancer progression. Their role in the oncogenic process is thought to be associated with an increase in their levels, since they have both been found to be overexpressed in at least eight different types of cancer [16] [17] [18] [19] [20] [21] [48] [49] [50] [51] [52] [53] . In view of the detrimental consequences resulting from altered levels of TBX3, as seen both in developmental disorders and in many cancers, the need to identify signalling pathways that regulate its expression is important.
In the present study, we describe a novel pathway by which TBX3 expression is regulated. We demonstrate for the first time that PMA treatment of several cell lines leads to a timedependent increase in TBX3 mRNA and protein levels, and we provide compelling evidence that this results from a PKCdependent process involving the AP-1 components c-Jun and JunB. Using in vitro and in vivo assays, we show that c-Jun and JunB directly bind and activate TBX3 at a non-consensus AP-1 binding site. The direct regulation of TBX3 by AP-1 seen in the present study is interesting because although AP-1 is known to be involved in cancer progression, only a few cancer-related genes have been shown to be directly bound and regulated by AP-1. For example, Kim et al. [54] showed that the extracellular-matrix-associated protein TIMP-3 (tissue inhibitor of metalloproteinases-3), which is able to suppress tumorigenicity or invasion in several model systems, is directly regulated by AP-1 components via several consensus and non-consensus AP-1 binding sites. Similarly, Kim et al. [55] showed direct binding of AP-1 to the promoter of the bombesin gene, which is implicated in human gastric cancers. Interestingly, we have recently shown that TBX2 is also induced by PMA but that it involves a mechanism independent of AP-1 [55a] . The results from our present study are therefore also significant because they describe a novel direct cancer-related target of AP-1.
Finally, we demonstrate using an in vitro cell migration assay that knockdown of TBX3 expression leads to a decrease in PMAinduced cell motility in the breast epithelial cancer MCF-7 cells. Although MCF-7 cells have poor migration ability [56] , PMA has been reported to enhance metastatic phenotypes, including cell motility, in these cells [57, 58] . E-cadherin, an important mediator of cell-cell interactions, has been shown to play a crucial role in breast tumour formation where it is frequently inactivated through several mechanisms, including transcriptional down-regulation [59] . Interestingly, we have recently shown that TBX3 directly represses E-cadherin and that overexpression of TBX3 in melanoma cells down-regulates endogenous E-cadherin expression [26] . Furthermore, we have shown that depletion of TBX3 results in an increase in E-cadherin mRNA and protein levels and a decrease in melanoma invasiveness in vitro [27] . Interestingly, several studies have reported that PMA treatment leads to the down-regulation of E-cadherin in epithelial-derived cancers [60, 61] . Furthermore, PMA was reported to increase the motility of a human rectal adenocarcinoma cell line, RCM-1, by down-regulating E-cadherin [62] . To our knowledge, the mechanism by which PMA down-regulates E-cadherin has still not been completely elucidated, and it is tempting to speculate that it could be through the up-regulation of TBX3.
Our findings reveal a new molecular mechanism that regulates TBX3 gene expression. Since this mechanism involving AP-1 is frequently implicated in carcinogenesis, our results contribute to the understanding of how TBX3 might be up-regulated in certain cancers. However, more detailed studies are required to uncover intermediate elements, such as co-factors, that are involved in this signalling pathway. This is particularly important, since several reports suggest that co-factors, for example bZIP proteins, play an important role in AP-1 mediated gene regulation [63] . The progress over the past few years on the role of TBX3 in cancer justifies the need to understand the principal mechanisms that mediate its regulation because it could uncover novel, more targeted and effective anti-cancer therapy.
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